Erasca
ERAS
Performance
About Erasca
Erasca is a clinical-stage biotechnology company focused on precision oncology. The company is dedicated to erasing cancer by targeting the RAS/MAPK signaling pathway, a frequently mutated route across multiple cancers. Its robust, modality-agnostic pipeline aims to shut down this pathway at various points to potentially benefit millions of patients worldwide. Erasca operates in the global cancer therapeutics space, developing targeted interventions with the goal of transforming cancer treatment outcomes.
Recent News
Erasca, Corvus, BioAge Target $500M+ Offerings
Erasca (ERAS) Adds 13%; Soars 310% YTD
BBOT Shakes up Leadership as RAS Competitors Get More Visibility
Acuta Capital Partners Invests $4.2 M for 1.35% Stake in Erasca’s Targeted Cancer Pipeline
STAT+: Can Erasca Be Biotech’s Next Big Thing? We’ll See
What’s Driving Erasca (ERAS)’s Nearly 355% YTD Return
Can Revolution’s 'Miracle' Pancreatic Cancer Drug Be Topped? Immuneering, Actuate Say Yes
Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer